Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7812653 in Early Symptomatic Alzheimer's Disease
NCT07234942Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2026
- Primary completion
- Mar 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing RO7812653 with Placebo (2 arms). Primary endpoints: Adverse Events at 40 weeks and Columbia-Suicide Severity Rating Scale at 40 weeks. Started Jan 2026; status: active, not recruiting.
02
Drugs
RO7812653
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07234942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07234942.